Thank you for your interest in post-marketing study information. The Post-Marketing Study Registration System on this website has ceased updates as of January 1, 2025, and related information is no longer provided on this platform.

For inquiries about post-marketing studies or related research information, we recommend exploring other resources that provide clinical trial information, such as the Taiwan Clinical Trials (TaiwanClinicalTrials.tw), clinical trial centers at major hospitals, or the website of Center for Drug Evaluation (https://www1.cde.org.tw/ct_taiwan/introduction.html).

We appreciate your understanding and continued support!

Company Name	Title of Study	Update Date
Novartis (Taiwan) Co., Ltd.	Retrospective, non-interventional, multi-center study evaluating safety of fingolimod in patients with multiple sclerosis in Taiwan	2016-01-05
Pfizer Inc.	Post-Marketing Surveillance study to observe INLYTA® treatment dosing pattern, safety and effectiveness in Taiwan real world routine practice	2015-11-25
Novartis (Taiwan) Co., Ltd.	A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of switching from salmeterol/fluticasone to QVA149 (indacaterol maleate/glycopyrronium bromide) in symptomatic COPD patients	2015-11-23
Novartis (Taiwan) Co., Ltd.	An observational, multi-center, prospective, open-label study to assess effectiveness, safety and tolerability of treatment with single pill combination of vildagliptin plus metformin(50mg/500mg, 50mg/850mg, 50mg/1000mg film-coated tablets)in type 2 diabetes mellitus patients in a real-world setting	2015-11-12
Chugai Pharma Taiwan Ltd.	Efficacy and safety evaluation of tocilizumab monotherapy in Taiwan population	2015-08-18
Boehringer Ingelheim Taiwan Limited	GLORIA-AF: Global Registry, on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation. (Phase II/III)	2015-06-24
Bayer Taiwan	A non-interventional, global, cross-sectional study to Check Atrial Fibrillation rates in patients 65 years or older by means of a device for opportunistic screening	2015-05-21
Pfizer Inc.	A Phase 3b/4 Randomized Double Blind Study Of 5 mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis	2015-04-29
Bayer Taiwan Co., Ltd.	Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia	2015-04-29
Astellas Pharma	An open-label, prospective interventional study of the tolerability and efficacy of oral Harnalidge® OCAS®(Tamsulosin) 0.4 mg in patients who are unsatisfied with the treatment of Tamsulosin 0.2 mg	2015-04-29